Proactive Investors
01 Sept 2026, 09:05 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Ondine Biomedical's phase 3 LANTERN study met its primary efficacy endpoint, showing a 40% relative reduction in surgical site infections. — Successful phase 3 results are the most critical catalyst for biotech firms, significantly increasing the probability of regulatory approval and commercialization.
+0.80Ondine Biomedical plans to request a pre-New Drug Application (NDA) meeting with the US FDA to discuss regulatory submissions. — This represents a concrete transition from clinical testing to the formal regulatory approval process in the world's largest healthcare market.
+0.50The topline review of the LANTERN study identified no treatment-related serious safety concerns. — A clean safety profile removes a primary risk factor that often leads to FDA rejection or restrictive labeling.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
3h ago
